However, the developed index had only low sensitivity (0.50; 95% CI, 0.39-0.61) and moderate specificity (0.63; 95% CI, 0.51-0.75), knowing that the reference test was a consensus medical decision ...

Tisotumab vedotin for recurrent cervical cancer resulted in significantly longer survival outcomes compared with chemotherapy alone, according to results from a phase 3 randomized study published ...